Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19
Maxime Taquet, Quentin Dercon, Sierra Luciano, John R Geddes, Masud Husain, Paul J Harrison, Maxime Taquet, Quentin Dercon, Sierra Luciano, John R Geddes, Masud Husain, Paul J Harrison
Abstract
Background: Long-COVID refers to a variety of symptoms affecting different organs reported by people following Coronavirus Disease 2019 (COVID-19) infection. To date, there have been no robust estimates of the incidence and co-occurrence of long-COVID features, their relationship to age, sex, or severity of infection, and the extent to which they are specific to COVID-19. The aim of this study is to address these issues.
Methods and findings: We conducted a retrospective cohort study based on linked electronic health records (EHRs) data from 81 million patients including 273,618 COVID-19 survivors. The incidence and co-occurrence within 6 months and in the 3 to 6 months after COVID-19 diagnosis were calculated for 9 core features of long-COVID (breathing difficulties/breathlessness, fatigue/malaise, chest/throat pain, headache, abdominal symptoms, myalgia, other pain, cognitive symptoms, and anxiety/depression). Their co-occurrence network was also analyzed. Comparison with a propensity score-matched cohort of patients diagnosed with influenza during the same time period was achieved using Kaplan-Meier analysis and the Cox proportional hazard model. The incidence of atopic dermatitis was used as a negative control. Among COVID-19 survivors (mean [SD] age: 46.3 [19.8], 55.6% female), 57.00% had one or more long-COVID feature recorded during the whole 6-month period (i.e., including the acute phase), and 36.55% between 3 and 6 months. The incidence of each feature was: abnormal breathing (18.71% in the 1- to 180-day period; 7.94% in the 90- to180-day period), fatigue/malaise (12.82%; 5.87%), chest/throat pain (12.60%; 5.71%), headache (8.67%; 4.63%), other pain (11.60%; 7.19%), abdominal symptoms (15.58%; 8.29%), myalgia (3.24%; 1.54%), cognitive symptoms (7.88%; 3.95%), and anxiety/depression (22.82%; 15.49%). All 9 features were more frequently reported after COVID-19 than after influenza (with an overall excess incidence of 16.60% and hazard ratios between 1.44 and 2.04, all p < 0.001), co-occurred more commonly, and formed a more interconnected network. Significant differences in incidence and co-occurrence were associated with sex, age, and illness severity. Besides the limitations inherent to EHR data, limitations of this study include that (i) the findings do not generalize to patients who have had COVID-19 but were not diagnosed, nor to patients who do not seek or receive medical attention when experiencing symptoms of long-COVID; (ii) the findings say nothing about the persistence of the clinical features; and (iii) the difference between cohorts might be affected by one cohort seeking or receiving more medical attention for their symptoms.
Conclusions: Long-COVID clinical features occurred and co-occurred frequently and showed some specificity to COVID-19, though they were also observed after influenza. Different long-COVID clinical profiles were observed based on demographics and illness severity.
Conflict of interest statement
I have read the journal’s policy and the authors of this manuscript have the following competing interests: SL is an employee of TriNetX Inc. The other authors report no interests to declare.
Figures
References
- Callard F, Perego E. How and why patients made Long Covid. Soc Sci Med. 2021;268:113426. doi: 10.1016/j.socscimed.2020.113426
- The Lancet. Facing up to long COVID. Lancet. 2020;396:1861. doi: 10.1016/S0140-6736(20)32662-3
- Meeting the challenge of long COVID. Nat Med. 2020;26:1803. doi: 10.1038/s41591-020-01177-6
- Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al.. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601–15. doi: 10.1038/s41591-021-01283-z
- Del Rio C, Collins LF, Malani P. Long-term Health Consequences of COVID-19. JAMA. 2020. doi: 10.1001/jama.2020.19719
- Butler M, Pollak TA, Rooney AG, Michael BD, Nicholson TR. Neuropsychiatric complications of covid-19. BMJ. 2020;371:m3871. doi: 10.1136/bmj.m3871
- Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020:m3026. doi: 10.1136/bmj.m3026
- Gorna R, MacDermott N, Rayner C, O’Hara M, Evans S, Agyen L, et al.. Long COVID guidelines need to reflect lived experience. Lancet. 2021;397:455–7. doi: 10.1016/S0140-6736(20)32705-7
- Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y, et al.. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact. EClinicalMedicine. 2021. Online first, July 15, 2021.
- Writing Committee for the COMEBAC Study Group, Morin L, Savale L, Pham T, Colle R, Figueiredo S, et al.. Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. JAMA. 2021;325:1525–1534. doi: 10.1001/jama.2021.3331
- Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al.. Attributes and predictors of long COVID. Nat Med. 2021. doi: 10.1038/s41591-021-01292-y
- Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al.. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220–32. doi: 10.1016/S0140-6736(20)32656-8
- Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416–27. doi: 10.1016/S2215-0366(21)00084-5
- Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequalae of COVID-19. Nature. 2021. doi: 10.1038/s41586-021-03553-9
- Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8:130–40. doi: 10.1016/S2215-0366(20)30462-4
- de Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, et al.. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020. doi: 10.1016/S1473-3099(20)30371-6
- Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al.. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–6. doi: 10.1038/s41586-020-2521-4
- Daugherty SE, Guo Y, Heath K, Dasmariñas MC, Jubilo KG, Samranvedhya J, et al.. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021;373:n1098. doi: 10.1136/bmj.n1098
- Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55.
- Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015;314:1637–8. doi: 10.1001/jama.2015.13480
- Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002. pp. 2175–2197. doi: 10.1002/sim.1203
- Dice LR. Measures of the amount of ecologic association between species. Ecology. 1945;26:297–302.
- Barrat A, Barthelemy M, Pastor-Satorras R, Vespignani A. The architecture of complex weighted networks. Proc Natl Acad Sci. 2004:3747–3752. doi: 10.1073/pnas.0400087101
- Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al.. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan China. Clin Infect Dis. 2020;71:762–8. doi: 10.1093/cid/ciaa248
- Hampshire A, Trender W, Chamberlain SR, Jolly A, Grant JE, Patrick F, et al.. Cognitive deficits in people who have recovered from COVID-19. EClinicalMedicine. 2021Jul;23:101044.
- Casey JA, Schwartz BS, Stewart WF, Adler NE. Using Electronic Health Records for Population Health Research: A Review of Methods and Applications. Annu Rev Public Health. 2016;37:61–81. doi: 10.1146/annurev-publhealth-032315-021353
- Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363–74. doi: 10.1038/s41577-020-0311-8
- Dani M, Dirksen A, Taraborrelli P, Torocastro M. Autonomic dysfunction in “long COVID”: rationale, physiology and management strategies. Clin Dermatol 2021. Available from: . doi: 10.7861/clinmed.2020-0896
- Altmann DM, Boyton RJ. Decoding the unknowns in long covid. BMJ. 2021. Available from: doi: 10.1136/bmj.n132
- Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi: 10.1136/bmj.n136
- Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al.. Persistent symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft quality principles for services. BMC Health Serv Res. 2020. doi: 10.1186/s12913-020-06001-y
Source: PubMed